BioLineRx (BLRX) Interest Expenses (2011 - 2026)

BioLineRx's Interest Expenses history runs 14 years deep, the most recent figure standing at $2.3 million for Q4 2025.

• In Q4 2025, Interest Expenses fell 43.0% year-over-year to $2.3 million; the TTM figure through Dec 2025 stood at $1.3 million (up 300.31% YoY), while the FY2025 annual figure was -$1.3 million, down 114.04% from the prior year.
• Interest Expenses for Q4 2025 stood at $2.3 million, up from -$304000.0 in the prior quarter.
• The five-year high for Interest Expenses was $5.3 million in Q4 2023, with the low at -$2.1 million in Q2 2024.
• The 5-year median for Interest Expenses is -$301500.0 (2021), against an average of -$17700.0.
• The sharpest annual moves came in 2022 and 2023: Interest Expenses tumbled 550.0% in 2022, then soared 497.44% in 2023.
• BioLineRx's Interest Expenses stood at -$204000.0 in 2021, then sank by 550.0% to -$1.3 million in 2022, then jumped by 497.44% to $5.3 million in 2023, then fell by 24.1% to $4.0 million in 2024, then tumbled by 43.0% to $2.3 million in 2025.
• Business Quant data shows BLRX's Interest Expenses at $2.3 million in Q4 2025, -$304000.0 in Q3 2025, and -$276000.0 in Q2 2025.